“As our field evolves, we must consider how we are training the next generation of hematologists and oncologists and whether that training is keeping pace with today’s rapidly changing and more subspecialized practice landscape,” according to Dr. Matthew Kurian.
PURPOSE Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry…
MicroabstractTreatment options for patients with relapsed/refractory multiple myeloma (RRMM) after relapse from allogeneic stem cell transplant (alloSCT) are needed. This study provides data around suitability…
FLC-MS can detect persistent light chains in a significant proportion of patients in a conventional hematologic CR.Patients with no detectable FLC by FLC-M
Key Points. CHIP is more prevalent in AL amyloidosis patients than in the general populationCHIP presence was associated with the presence of t(11;14) and
Key Points. Better clinical responses to teclistamab correlate with a more functional initial immune T-cell repertoire in the periphery and tumor siteMore
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
